Further Clinical Testing Of BZL101 In Advanced Breast Cancer Demonstrates Favorable E
 

Bionovo Inc. (Nasdaq: BNVI) announced results from a second ongoing clinical trial of BZL101, an oral drug candidate, in patients with refractory, metastatic breast cancer. The data, which were presented at the American Society of Clinical Oncology 44th Annual Meeting, showed that BZL101, at higher doses, continues to have a favorable safety and tolerability profile and shows ongoing evidence of clinical activity in women with advanced breast cancer.

More...